tiprankstipranks
Trending News
More News >
Agilon Health (AGL)
NYSE:AGL
US Market

Agilon Health (AGL) Stock Forecast & Price Target

Compare
287 Followers
See the Price Targets and Ratings of:

AGL Analyst Ratings

Hold
13Ratings
Hold
3 Buy
8 Hold
2 Sell
Based on 13 analysts giving stock ratings to
Agilon
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AGL Stock 12 Month Forecast

Average Price Target

$4.60
▲(112.96%Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Agilon Health in the last 3 months. The average price target is $4.60 with a high forecast of $7.50 and a low forecast of $2.40. The average price target represents a 112.96% change from the last price of $2.16.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.25,2.6538461538461537,3.0576923076923075,3.4615384615384617,3.8653846153846154,4.269230769230769,4.673076923076923,5.076923076923077,5.480769230769231,5.884615384615385,6.288461538461538,6.6923076923076925,7.096153846153847,{"y":7.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.25,2.4307692307692306,2.6115384615384616,2.792307692307692,2.973076923076923,3.1538461538461537,3.3346153846153843,3.5153846153846153,3.696153846153846,3.8769230769230765,4.0576923076923075,4.238461538461538,4.419230769230769,{"y":4.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.25,2.2615384615384615,2.273076923076923,2.2846153846153845,2.296153846153846,2.3076923076923075,2.319230769230769,2.330769230769231,2.3423076923076924,2.353846153846154,2.3653846153846154,2.376923076923077,2.3884615384615384,{"y":2.4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.96,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.7,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$7.50Average Price Target$4.60Lowest Price Target$2.40
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on AGL
TipRanks AITipRanks
Not Ranked
TipRanks
$2.5
Hold
15.74%
Upside
Reiterated
06/05/25
Agilon Health's overall stock score reflects significant financial difficulties, with persistent losses and weak cash positions being the most critical factors. The bearish technical indicators further affect the stock outlook, while the earnings call reveals both potential and ongoing challenges. Valuation concerns also weigh heavily due to negative earnings and lack of dividends.
Bernstein Analyst forecast on AGL
Lance WilkesBernstein
Bernstein
$7.5
Buy
247.22%
Upside
Reiterated
06/06/25
Bernstein Keeps Their Buy Rating on Agilon Health (AGL)
Truist Financial Analyst forecast on AGL
Jailendra SinghTruist Financial
Truist Financial
Hold
Reiterated
05/21/25
Truist Financial Reaffirms Their Hold Rating on Agilon Health (AGL)
Wells Fargo Analyst forecast on AGL
Stephen BaxterWells Fargo
Wells Fargo
$6$5
Buy
131.48%
Upside
Reiterated
05/12/25
Agilon Health: Buy Rating Supported by Medicare Advantage Leverage and Margin Recovery
Barclays
$2$3
Sell
38.89%
Upside
Reiterated
05/08/25
Barclays Remains a Sell on Agilon Health (AGL)
Leerink Partners Analyst forecast on AGL
Whit MayoLeerink Partners
Leerink Partners
$3.5$4.5
Hold
108.33%
Upside
Reiterated
05/07/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Agilon Health (NYSE: AGL)
Bank of America Securities Analyst forecast on AGL
Joanna GajukBank of America Securities
Bank of America Securities
$2.4
Sell
11.11%
Upside
Reiterated
05/07/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Agilon Health (NYSE: AGL) and Waters (NYSE: WAT)
Needham
Hold
Reiterated
05/07/25
Cautious Hold Rating on Agilon Health Amid Uncertainties Despite Strong Q1 FY25 Performance
TD Cowen
$6$4
Hold
85.19%
Upside
Reiterated
05/07/25
TD Cowen Sticks to Their Hold Rating for Agilon Health (AGL)
Evercore ISI
$3$5
Hold
131.48%
Upside
Reiterated
05/07/25
Evercore ISI Keeps Their Hold Rating on Agilon Health (AGL)
William Blair Analyst forecast on AGL
Ryan DanielsWilliam Blair
William Blair
Hold
Reiterated
05/06/25
Agilon Health: Hold Rating Amid Positive Results and Cost Concerns
Citizens JMP
Hold
Reiterated
04/28/25
Citizens JMP reiterates Market Perform Rating on agilon health Inc (AGL)Citizens JMP analyst Constantine Davides reiterated a Market Perform rating on agilon health Inc (NYSE: AGL).
Citi
$3.25$5
Buy
131.48%
Upside
Upgraded
04/23/25
Agilon Health upgraded to Buy from Neutral at CitiAgilon Health upgraded to Buy from Neutral at Citi
Robert W. Baird Analyst forecast on AGL
Michael HaRobert W. Baird
Robert W. Baird
$6$5
Hold
131.48%
Upside
Reiterated
04/15/25
Agilon Health downgraded to Neutral from Outperform at BairdAgilon Health downgraded to Neutral from Outperform at Baird
Benchmark Co. Analyst forecast on AGL
Bill SutherlandBenchmark Co.
Benchmark Co.
$3$4
Buy
85.19%
Upside
Reiterated
02/27/25
Agilon Health's Strategic Positioning and Financial Outlook Justify Buy Rating
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on AGL
TipRanks AITipRanks
Not Ranked
TipRanks
$2.5
Hold
15.74%
Upside
Reiterated
06/05/25
Agilon Health's overall stock score reflects significant financial difficulties, with persistent losses and weak cash positions being the most critical factors. The bearish technical indicators further affect the stock outlook, while the earnings call reveals both potential and ongoing challenges. Valuation concerns also weigh heavily due to negative earnings and lack of dividends.
Bernstein Analyst forecast on AGL
Lance WilkesBernstein
Bernstein
$7.5
Buy
247.22%
Upside
Reiterated
06/06/25
Bernstein Keeps Their Buy Rating on Agilon Health (AGL)
Truist Financial Analyst forecast on AGL
Jailendra SinghTruist Financial
Truist Financial
Hold
Reiterated
05/21/25
Truist Financial Reaffirms Their Hold Rating on Agilon Health (AGL)
Wells Fargo Analyst forecast on AGL
Stephen BaxterWells Fargo
Wells Fargo
$6$5
Buy
131.48%
Upside
Reiterated
05/12/25
Agilon Health: Buy Rating Supported by Medicare Advantage Leverage and Margin Recovery
Barclays
$2$3
Sell
38.89%
Upside
Reiterated
05/08/25
Barclays Remains a Sell on Agilon Health (AGL)
Leerink Partners Analyst forecast on AGL
Whit MayoLeerink Partners
Leerink Partners
$3.5$4.5
Hold
108.33%
Upside
Reiterated
05/07/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Agilon Health (NYSE: AGL)
Bank of America Securities Analyst forecast on AGL
Joanna GajukBank of America Securities
Bank of America Securities
$2.4
Sell
11.11%
Upside
Reiterated
05/07/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Agilon Health (NYSE: AGL) and Waters (NYSE: WAT)
Needham
Hold
Reiterated
05/07/25
Cautious Hold Rating on Agilon Health Amid Uncertainties Despite Strong Q1 FY25 Performance
TD Cowen
$6$4
Hold
85.19%
Upside
Reiterated
05/07/25
TD Cowen Sticks to Their Hold Rating for Agilon Health (AGL)
Evercore ISI
$3$5
Hold
131.48%
Upside
Reiterated
05/07/25
Evercore ISI Keeps Their Hold Rating on Agilon Health (AGL)
William Blair Analyst forecast on AGL
Ryan DanielsWilliam Blair
William Blair
Hold
Reiterated
05/06/25
Agilon Health: Hold Rating Amid Positive Results and Cost Concerns
Citizens JMP
Hold
Reiterated
04/28/25
Citizens JMP reiterates Market Perform Rating on agilon health Inc (AGL)Citizens JMP analyst Constantine Davides reiterated a Market Perform rating on agilon health Inc (NYSE: AGL).
Citi
$3.25$5
Buy
131.48%
Upside
Upgraded
04/23/25
Agilon Health upgraded to Buy from Neutral at CitiAgilon Health upgraded to Buy from Neutral at Citi
Robert W. Baird Analyst forecast on AGL
Michael HaRobert W. Baird
Robert W. Baird
$6$5
Hold
131.48%
Upside
Reiterated
04/15/25
Agilon Health downgraded to Neutral from Outperform at BairdAgilon Health downgraded to Neutral from Outperform at Baird
Benchmark Co. Analyst forecast on AGL
Bill SutherlandBenchmark Co.
Benchmark Co.
$3$4
Buy
85.19%
Upside
Reiterated
02/27/25
Agilon Health's Strategic Positioning and Financial Outlook Justify Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agilon Health

1 Month
xxx
Success Rate
9/21 ratings generated profit
43%
Average Return
-1.60%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of -1.60% per trade.
3 Months
xxx
Success Rate
5/14 ratings generated profit
36%
Average Return
-2.77%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -2.77% per trade.
1 Year
Sean DodgeRBC Capital
Success Rate
1/14 ratings generated profit
7%
Average Return
-46.95%
reiterated a buy rating 3 months ago
Copying Sean Dodge's trades and holding each position for 1 Year would result in 7.14% of your transactions generating a profit, with an average return of -46.95% per trade.
2 Years
xxx
Success Rate
1/14 ratings generated profit
7%
Average Return
-63.89%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 7.14% of your transactions generating a profit, with an average return of -63.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AGL Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
1
1
2
4
5
Buy
4
5
6
4
3
Hold
19
17
17
14
11
Sell
2
2
2
2
2
Strong Sell
0
0
0
0
0
total
26
25
27
24
21
In the current month, AGL has received 8 Buy Ratings, 11 Hold Ratings, and 2 Sell Ratings. AGL average Analyst price target in the past 3 months is 4.60.
Each month's total comprises the sum of three months' worth of ratings.

AGL Financial Forecast

AGL Earnings Forecast

Next quarter’s earnings estimate for AGL is -$0.10 with a range of -$0.16 to -$0.05. The previous quarter’s EPS was $0.03. AGL beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year AGL has Outperformed its overall industry.
Next quarter’s earnings estimate for AGL is -$0.10 with a range of -$0.16 to -$0.05. The previous quarter’s EPS was $0.03. AGL beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year AGL has Outperformed its overall industry.

AGL Sales Forecast

Next quarter’s sales forecast for AGL is $1.47B with a range of $1.46B to $1.50B. The previous quarter’s sales results were $1.53B. AGL beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year AGL has Outperformed its overall industry.
Next quarter’s sales forecast for AGL is $1.47B with a range of $1.46B to $1.50B. The previous quarter’s sales results were $1.53B. AGL beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year AGL has Outperformed its overall industry.

AGL Stock Forecast FAQ

What is AGL’s average 12-month price target, according to analysts?
Based on analyst ratings, Agilon Health’s 12-month average price target is 4.60.
    What is AGL’s upside potential, based on the analysts’ average price target?
    Agilon Health has 112.96% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AGL a Buy, Sell or Hold?
          Agilon Health has a consensus rating of Hold which is based on 3 buy ratings, 8 hold ratings and 2 sell ratings.
            What is Agilon Health’s price target?
            The average price target for Agilon Health is 4.60. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $7.50 ,the lowest forecast is $2.40. The average price target represents 112.96% Increase from the current price of $2.16.
              What do analysts say about Agilon Health?
              Agilon Health’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of AGL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis